S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The 3-Stock Retirement Blueprint (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
3rd Massive Dollar Upheaval Has Started (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The 3-Stock Retirement Blueprint (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
3rd Massive Dollar Upheaval Has Started (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The 3-Stock Retirement Blueprint (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
3rd Massive Dollar Upheaval Has Started (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The 3-Stock Retirement Blueprint (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
3rd Massive Dollar Upheaval Has Started (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:ADMP

Adamis Pharmaceuticals - ADMP Earnings Date, Estimates & Call Transcripts

$0.37
0.00 (0.00%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.37
$0.40
50-Day Range
$0.36
$0.54
52-Week Range
$0.31
$1.48
Volume
793,922 shs
Average Volume
1.08 million shs
Market Capitalization
$55.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Earnings Summary

Upcoming
Earnings Date
Aug. 10Confirmed
Actual EPS
(May. 16)
-$0.07 Missed By -$0.04
Consensus EPS
(May. 16)
-$0.03
Skip Charts & View Estimated and Actual Earnings Data

ADMP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADMP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Adamis Pharmaceuticals Analyst Forecasts

Current Year EPS Consensus Estimate: $-0.15 EPS
Next Year EPS Consensus Estimate: $-0.06 EPS

ADMP Earnings Date and Information

Adamis Pharmaceuticals last released its earnings results on May 16th, 2022. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.04. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $3.81 million. Adamis Pharmaceuticals has generated $0.00 earnings per share over the last year. Earnings for Adamis Pharmaceuticals are expected to grow in the coming year, from ($0.15) to ($0.06) per share. Adamis Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Wednesday, August 10th, 2022. Adamis Pharmaceuticals will be holding an earnings conference call on Wednesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call..

Adamis Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/10/2022
(Confirmed)
 ($0.04)       
5/16/2022Q1 2022($0.03)($0.07)($0.04)($0.07)$3.81 million$1.16 million    
3/31/202212/31/2021($0.04)($0.06)($0.02)    
11/22/2021Q3 2021($0.06)($0.03)+$0.03$0.02$0.76 million    
4/14/2021Q4($0.06)($0.24)($0.18)($0.08)$3.64 million  
11/14/20209/30/2020($0.05)($0.10)($0.05)($0.10)$8.15 million$4.30 million  
8/17/2020Q2 2020($0.07)($0.13)($0.06)($0.11)$5.00 million$3.93 million
5/18/2020Q1 2020($0.04)($0.15)($0.11)($0.05)$6.87 million$4.66 million  
3/30/2020Q4($0.0370)($0.08)($0.0430)($0.08)$5.60 million$5.54 million
11/12/2019Q3 2019($0.06)($0.12)($0.06)($0.10)$6.55 million$5.90 million  
8/8/2019Q2 2019($0.13)($0.16)($0.03)($0.16)$5.82 million$5.77 million  
5/9/20193/31/2019($0.15)($0.19)($0.04)($0.19)$5.95 million$4.91 million
3/15/2019Q4 2018($0.19)($0.28)($0.09)($0.28)$5.82 million$4.15 million
11/9/2018Q3 2018($0.15)($0.21)($0.06)($0.21)$5.39 million$3.83 million
8/10/2018Q2 2018($0.1870)($0.29)($0.1030)($0.29)$4.14 million$3.92 million
5/10/2018Q1 2018($0.17)($0.2280)($0.0580)($0.23)$3.34 million$3.18 million
3/15/2018Q4 2017($0.24)($0.24)($0.24)$2.84 million
11/14/2017Q3 2017($0.21)($0.21)($0.21)$3.39 million
8/14/2017Q2 2017($0.19)($0.19)($0.19)$3.81 million
5/12/2017Q1 2017($0.21)($0.26)($0.05)($0.26)$3.00 million$3.04 million
11/14/2016Q3 2016($0.48)($0.41)+$0.07($0.41)$2.08 million
8/15/2016Q2($0.37)($0.37)($0.37)$1.93 million
5/13/2016Q1 2016($0.48)($0.48)($0.48)
3/23/2016Q4 2015($0.21)($0.21)($0.21)
11/9/2015Q3 2015($0.24)($0.24)($0.24)
8/7/2015Q2 2015($0.27)($0.27)($0.27)
5/14/2015Q1 2015($0.32)($0.32)($0.32)
11/14/2014Q3 2014($0.20)($0.20)($0.20)
8/13/2014Q2 2014($0.27)($0.27)($0.27)
6/23/2014Q1 2014($0.18)($0.18)($0.18)
2/14/2014Q4 2013($0.82)($0.82)($0.82)
11/13/2013Q3 2013($0.17)($0.17)($0.17)
8/19/2013Q2 2013($2.89)($2.89)($2.89)
2/14/2012Q4 2011($0.19)($0.19)($0.19)
11/21/2011Q3 2011($0.27)($0.27)($0.27)
5/13/2009Q4 2008($0.19)($0.19)($0.19)












Adamis Pharmaceuticals Earnings - Frequently Asked Questions

When is Adamis Pharmaceuticals's earnings date?

Adamis Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Wednesday, August 10th, 2022. Learn more on ADMP's earnings history.

Did Adamis Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Adamis Pharmaceuticals (NASDAQ:ADMP) missed the analysts' consensus estimate of ($0.03) by $0.04 with a reported earnings per share (EPS) of ($0.07). Learn more on analysts' earnings estimate vs. ADMP's actual earnings.

How can I listen to Adamis Pharmaceuticals's earnings conference call?

The conference call for Adamis Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Adamis Pharmaceuticals's conference call transcript?

The conference call transcript for Adamis Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Adamis Pharmaceuticals generate each year?

Adamis Pharmaceuticals (NASDAQ:ADMP) has a recorded annual revenue of $2.21 million.

How much profit does Adamis Pharmaceuticals generate each year?

Adamis Pharmaceuticals (NASDAQ:ADMP) has a recorded net income of -$45.83 million. ADMP has generated $0.00 earnings per share over the last four quarters.

What is Adamis Pharmaceuticals's EPS forecast for next year?

Adamis Pharmaceuticals's earnings are expected to grow from ($0.15) per share to ($0.06) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:ADMP) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.